Foghorn Therapeutics Inc. FHTX
2.08 USD +0.21 (+10.96%)
Nov 9, 2026, 2:57 PM EST
1.89 Day range 2.12
1.79 52-week range 7.61
- YTD
- -61.57%
- 1 year
- -52.41%
News
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. (“Foghorn” or the “Company”) (NASDAQ: FHTX). Such investors are…
globenewswire.com Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines against challenging targets in oncology and…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Stablecoin Development (AMEX:SDEV) shares moved upwards by 66.9% to $6.11 during Friday's regular session. The company's market cap stands at $99.2 million. QTREX Quantum (NASDAQ:QTEX) stock…
benzinga.com Wedbush Downgrades Foghorn Therapeutics to Neutral, Lowers Price Target to $2 Wedbush analyst Robert Driscoll downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Outperform to Neutral and lowers the price target from $10 to $2.
benzinga.com Guggenheim Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5 Guggenheim analyst Michael Schmidt maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $12 to $5.
benzinga.com Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday Analysts raised targets for ACN, SYNA, ATRC and MPC; cut targets for CSX, NKE, MKC and FHTX, with ATRC downgraded to Hold.
benzinga.com This AST SpaceMobile Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Analysts downgraded FHTX, BUSE, ASTS, ATRC and EQBK; targets fell for BUSE, ASTS and EQBK but rose for ATRC.
benzinga.com HC Wainwright & Co. Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $13 to $5.
benzinga.com Nasdaq Gains 100 Points; ISM manufacturing PMI Slips In September U.S. stocks edged higher Thursday; Nasdaq rose 0.37%, energy led gains, Accenture surged 18%, and Corteva plunged 84%.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Nexalin Technology (NASDAQ:NXL) shares increased by 77.8% to $7.61 during Thursday's regular session. The company's market cap stands at $3.5 million. Stablecoin Development (AMEX:SDEV) stock…
benzinga.com Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal Foghorn Therapeutics stock drops as Eli Lilly ends partnership, prompting a 40% workforce cut to extend cash runway into 2029 while pivoting pipeline.
benzinga.com Dow Falls Over 200 Points; Micron Earnings Top Views U.S. stocks slipped Thursday as the Dow fell over 200 points; energy and oil rose, Micron beat estimates, and European markets declined.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-market session. The company's market cap stands at $10.1 million. Stablecoin Development (AMEX:SDEV)…
benzinga.com Foghorn Therapeutic Announces That The Company And Lilly Will Not Advance The FHD-909 Program Into The Clinical Development Expansion Phase Following a review of clinical data from the Phase 1 dose escalation trial of FHD-909 (LY4050784), Foghorn and Lilly have decided not to advance the program into the clinical development expansion…
benzinga.com Foghorn Therapeutics Q2 EPS $(0.10) Beats $(0.23) Estimate, Sales $16.072M Beat $5.995M Estimate Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.23) by 54.55 percent. This is a 64.29 percent increase over losses…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Foghorn Therapeutics Q1 EPS $(0.29), Inline, Sales $3.267M Miss $7.438M Estimate Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.29) per share which met the analyst consensus estimate. This is a 3.33 percent increase over losses of $(0.30) per share from the…
- benzinga.com Foghorn Therapeutics Presents New Preclinical Data For Selective SMARCA2 Inhibitor FHD-909 And For Selective CBP, EP300 And ARID1B Degrader Programs - Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models- Selective…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com Foghorn Therapeutics To Share New Cancer Drug Data At Major Research Conference Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today…
benzinga.com Wedbush Reiterates Outperform on Foghorn Therapeutics, Maintains $10 Price Target Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and maintains $10 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $13 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $13 price target.- benzinga.com Reported Friday, Foghorn Therapeutics Secures $50M Equity Financing, Advances Oncology Pipeline, And Extends $208.9M Cash Runway Into First Half Of 2028 Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026Phase 1…
- benzinga.com BTIG Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $11 BTIG analyst Jeet Mukherjee initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $11.
- benzinga.com Stifel Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $12 Stifel analyst Laura Prendergast initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $12.
benzinga.com This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - benzinga.com Guggenheim Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $12 Guggenheim analyst Michael Schmidt initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $12.
- benzinga.com Foghorn Therapeutics Q3 EPS $(0.25) Beats $(0.30) Estimate, Sales $8.153M Beat $6.197M Estimate Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.30) by 17.76 percent. This is a 19.35 percent increase over losses…
- benzinga.com Foghorn Therapeutics To Present Updates For Selective ARID1B, Selective CBP, And Selective EP300 Degrader Programs, During Foghorn-Hosted Virtual Investor Event - Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors -…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com Foghorn Therapeutics Q2 EPS $(0.28) Beats $(0.33) Estimate, Sales $7.557M Beat $6.498M Estimate Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.33) by 13.85 percent. This is a 37.78 percent increase over losses…
- benzinga.com JMP Securities Reiterates Market Outperform on Foghorn Therapeutics, Maintains $9 Price Target JMP Securities analyst Silvan Tuerkcan reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Market Outperform and maintains $9 price target.
- benzinga.com Foghorn Therapeutics Q1 EPS $(0.30) Beats $(0.31) Estimate, Sales $5.95M Beat $5.82M Estimate Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.31) by 3.23 percent. This is a 49.15 percent increase over losses of…
- benzinga.com JMP Securities Reiterates Market Outperform on Foghorn Therapeutics, Maintains $9 Price Target JMP Securities analyst Silvan Tuerkcan reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Market Outperform and maintains $9 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $13 Price Target HC Wainwright & Co. analyst Andres Maldonado reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $13 price target.
benzinga.com Foghorn Therapeutics Presents New Data On Selective SMARCA2 Inhibitor FHD-909 And Selective CBP And Selective EP300 Degrader Programs FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population- Preclinical synergistic anti-tumor activity…
benzinga.com This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday - benzinga.com JMP Securities Initiates Coverage On Foghorn Therapeutics with Market Outperform Rating, Announces Price Target of $9 JMP Securities analyst Silvan Tuerkcan initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Market Outperform rating and announces Price Target of $9.
benzinga.com Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - benzinga.com Foghorn Therapeutics Will Present New Preclinical Data For Selective SMARCA2 Inhibitor FHD-909 And Selective CBP And EP300 Degrader Programs At 2025 AACR Meeting In Chicago April 24-20, 2025 CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $13 Price Target HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $13 price target.
- benzinga.com Foghorn Therapeutics FY 2024 GAAP EPS $(1.58) Beats $(1.61) Estimate, Sales $22.602M Miss $30.713M Estimate Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(1.58) per share which beat the analyst consensus estimate of $(1.61) by 1.86 percent. This is a 32.48 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday 
benzinga.com B. Riley Securities Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $10 B. Riley Securities analyst Kalpit Patel initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $10.- benzinga.com HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Lowers Price Target to $13 HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $20 to $13.
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Jefferies Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $14 Jefferies analyst Kelly Shi maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $18 to $14.
- benzinga.com Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program.